Stockreport

Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Viridian Therapeutics, Inc.  (VRDN) 
PDF - Positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED) - - VRDN-002 achieved a substantially exten [Read more]